Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17580939 | 0.89 | AR (0.76) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL11036255 | 0.89 | MAPT (0.52) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL7062464 | 0.85 | HIF1A (0.63) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL15254318 | 0.84 | ALDH1A1 (0.74) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL376300 | 0.83 | HIF1A (0.61) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL27822729 | 0.81 | HTT (0.49) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL27841770 | 0.81 | HTT (0.49) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL868711 | 0.80 | AR (0.85) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL12363856 | 0.80 | AR (0.85) | HIF1AHTTARKMT2AMEN1 | |
| SCHEMBL11964790 | 0.80 | HTT (0.67) | HIF1AHTTARKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3162352-A1 | METHODS AND COMPOSITIONS OF REACTIVE MATERIALS FOR DENTAL PROCEDURES | Kerr Corporation (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170112722-A1 | METHODS AND COMPOSITIONS OF REACTIVE MATERIALS FOR DENTAL PROCEDURES | KERR CORPORATION | 2017-04-27 | — | — | US | disclosed |
| EP-1497696-B1 | PHOTOCURABLE COMPOSITIONS CONTAINING REACTIVE PARTICLES | 3D SYSTEMS INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| EP-2674161-A1 | FMO3 inhibitors for treating pain | Akron Molecules GmbH (AT) | 2013-12-18 | — | — | EP | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-1256032-B1 | LIQUID, RADIATION-CURABLE COMPOSITION, ESPECIALLY FOR STEREOLITHOGRAPHY | HUNTSMAN ADV MAT SWITZERLAND (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-7307123-B2 | Photocurable compositions containing reactive particles | HUNTSMAN ADVANCED MATERIALS AMERICAS INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20050228064-A1 | Liquid radiation-curable composition, especially for stereolithography | HUNTSMAN ADVANCED MATERIALS AMERICAS INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050175925-A1 | Photocurable compositions containing reactive particles | 3D SYSTEMS, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20010046642-A1 | Liquid, radiation-curable composition, especially for stereolithography | DEUTSCHE BANK AG NEW YORK BRANCH, AS AGENT | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | HIF1A 722/4885HTT 384/4885AR 3036/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | HIF1A 722/4885HTT 384/4885AR 3036/4885 |
| US-20170112722-A1 | METHODS AND COMPOSITIONS OF REACTIVE MATERIALS FOR DENTAL PROCEDURES | PHOSPHO1, PIEZO1, ERCC1 | HIF1A 1946/4885HTT 4140/4885AR 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.